Clinical Trials Logo

Bacterial Infections clinical trials

View clinical trials related to Bacterial Infections.

Filter by:

NCT ID: NCT03816956 Recruiting - Clinical trials for Staphylococcus Aureus

Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301

AR-301-002
Start date: February 2019
Phase: Phase 3
Study type: Interventional

AR-301 is being evaluated as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S. aureus infection.

NCT ID: NCT03801213 Not yet recruiting - Clinical trials for Urinary Tract Infection Bacterial

Evaluation of Urine Samples Obtained by Bladder Stimulation for the Diagnosis of Urinary Tract Infection in Infants

EEStiVeN
Start date: June 2019
Phase: N/A
Study type: Interventional

Urinary tract infection (UTI) is the most common serious bacterial infection among infants. Suprapubic aspiration and bladder catheterization are considered as the gold standard by the American Academy of Pediatrics for the diagnosis, yet it is painful and invasive. In contrast, the bladder stimulation technique has been shown to be a quick and non-invasive approach to collect urine in young infants. Actually, the investigators don't have data on bacterial contamination rates for clean-catch midstream urine collections using this technique

NCT ID: NCT03780140 Available - Clinical trials for Bacterial Infections

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

Start date: n/a
Phase:
Study type: Expanded Access

Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.

NCT ID: NCT03774940 Completed - Nephrolithiasis Clinical Trials

Blood Parameters as a Predictor of Fever After Percutaneous Nephrolithotomy

Start date: January 1, 2005
Phase: N/A
Study type: Interventional

To investigate the relationship between neutrophil count, lymphocyte count, neutrophil-to-lymphocyte count ratio (NLR), and postoperative fever in patients undergoing percutaneous nephrolithotomy (PNL).

NCT ID: NCT03767374 Recruiting - HIV Infections Clinical Trials

Risk-factors for Multidrug-resistant Bacteria Colonization Among Patients at High Risk of STIs

BMR-IST
Start date: May 11, 2018
Phase:
Study type: Observational

The aim of this study is to identify risk factors and prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria colonization among patients at high risk of STIs

NCT ID: NCT03761043 Recruiting - Clinical trials for Bacterial Infections

Nurse Promotion of IV to PO Antimicrobial Conversion

FERN-IPO
Start date: January 7, 2019
Phase: N/A
Study type: Interventional

This is a prospective, quasi-experimental, historically controlled study to evaluate if a behavioural change intervention informed by the COM-B model of behaviour change can improve nurses' self-perceived capability, opportunity, and motivation to engage in the assessment of patients who may be appropriate for IV to PO antimicrobial conversion. This study also seeks to determine if this translates into an increase in IV to PO antimicrobial conversion rates in the acute care setting.

NCT ID: NCT03752476 Not yet recruiting - Clinical trials for Antibiotic Resistant Infection

Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

INOR Blact
Start date: January 1, 2019
Phase:
Study type: Observational

This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study. Cases are colonized patient by multidrug resistant bacteria hospitalized in intensive care during the fist hospitalization in intensive care. Temoin are patients with the same characteristics than case but no colonized by multidrug resistant bacteria.

NCT ID: NCT03752424 Recruiting - Clinical trials for Infection, Bacterial

Topical Silver Nanoparticles for Microbial Activity

Start date: January 13, 2019
Phase: Phase 1
Study type: Interventional

Silver nanoparticles are one of most nanoparticles use nowadays in the research area because it has specific physical and chemical properties, in medical fields silver nanoparticles can involve in diagnostic and treatment processes. Silver nanoparticles have antibacterial, antiviral, antifungal, antiangiogenic, antioxidant, cosmetics, antitumor, anti-inflammatory, the drug carrier, imaging, water treatment, and biosensing effects. Silver nanoparticles prepared with reducing agent tri-sodium citrate then incorporated in a topical cream to obtain a significant inhibition of the bacterial strains, inhibition of growth of bacterial strains in the face or other parts in the bodies.

NCT ID: NCT03747497 Recruiting - Clinical trials for Gram-Positive Bacterial Infections

Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

Start date: November 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether contezolid acefosamil is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections

NCT ID: NCT03738683 Not yet recruiting - Clinical trials for Bacterial Infections

Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients

PICTAR
Start date: February 1, 2019
Phase:
Study type: Observational

Optimal understanding of piperacillin-tazobactam pharmacokinetics in critically ill patients is lacking resulting in large variation of achieved exposure and possible inadequate therapy. The investigators hypothesize that drug dosing based on CKD-EPIcr-cys provides a useful method to individualize and optimize therapy for piperacillin-tazobactam and eventually improve outcome. In a multi-centre, observational, open-label study the investigators aim to define PK of free drug concentrations of both piperacillin and tazobactam in ICU patients and define a PK model for estimation of renal function that most accurately predicts piperacillin and tazobactam clearance.